- Home
- ETON vs EVGO Comparison
ETON vs EVGO Comparison
Compare ETON & EVGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- EVGO
- Stock Information
- Founded
- ETON 2017
- EVGO 2010
- Country
- ETON United States
- EVGO United States
- Employees
- ETON N/A
- EVGO N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- EVGO Other Specialty Stores
- Sector
- ETON Health Care
- EVGO Consumer Discretionary
- Exchange
- ETON Nasdaq
- EVGO Nasdaq
- Market Cap
- ETON 428.5M
- EVGO 376.5M
- IPO Year
- ETON 2018
- EVGO N/A
- Fundamental
- Price
- ETON $17.33
- EVGO $3.83
- Analyst Decision
- ETON Strong Buy
- EVGO Strong Buy
- Analyst Count
- ETON 3
- EVGO 10
- Target Price
- ETON $27.67
- EVGO $5.78
- AVG Volume (30 Days)
- ETON 221.4K
- EVGO 3.9M
- Earning Date
- ETON 05-13-2025
- EVGO 05-06-2025
- Dividend Yield
- ETON N/A
- EVGO N/A
- EPS Growth
- ETON N/A
- EVGO N/A
- EPS
- ETON N/A
- EVGO N/A
- Revenue
- ETON $39,011,000.00
- EVGO $276,954,000.00
- Revenue This Year
- ETON $92.33
- EVGO $39.82
- Revenue Next Year
- ETON $52.62
- EVGO $32.12
- P/E Ratio
- ETON N/A
- EVGO N/A
- Revenue Growth
- ETON 23.29
- EVGO 45.15
- 52 Week Low
- ETON $3.18
- EVGO $1.78
- 52 Week High
- ETON $18.41
- EVGO $9.07
- Technical
- Relative Strength Index (RSI)
- ETON 68.29
- EVGO 79.08
- Support Level
- ETON $16.43
- EVGO $2.66
- Resistance Level
- ETON $17.49
- EVGO $4.17
- Average True Range (ATR)
- ETON 0.88
- EVGO 0.23
- MACD
- ETON 0.19
- EVGO 0.13
- Stochastic Oscillator
- ETON 92.78
- EVGO 81.13
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About EVGO EVgo Inc.
EVgo owns and operates a public direct current fast-charging network in the US. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the US. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners to locate and deploy its EV charging infrastructure.